Physician profile
William G Lay
NPI 1902922560
$9,324.84
in general payments reported to CMS, 2019-2025
17 companies · $1,401 in 2025
The $1,401 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $781 · 2020: $1,535 · 2021: $1,115 · 2022: $1,149 · 2023: $805 · 2024: $2,539 · 2025: $1,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,745.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $2,513.45 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $1,799.21 | 2020-2025 | Total30, Dailies Total1, Precision 1 |
| Visioneering Technologies, INC. | $1,307.65 | 2024 | |
| Biotissue Holdings INC. | $928.20 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $500.52 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $422.56 | 2022-2025 | Xiidra, Miebo, Infuse |
| Oyster Point Pharma, INC. | $309.11 | 2022-2024 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $260.89 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $250.35 | 2022-2023 | |
| Lombart Brothers, INC. | $183.94 | 2019-2020 | |
| Abbvie INC. | $179.90 | 2022-2025 | |
| Dompe US, INC. | $147.20 | 2024-2025 | Oxervate |
| Coopervision INC. | $137.62 | 2024 | Myday Contact Lens |
| Tarsus Pharmaceuticals, INC. | $129.44 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $128.25 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $126.55 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.